Entera Bio Ltd. Cash and Short Term Investments

Cash and Short Term Investments of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cash and Short Term Investments growth rates and interactive chart. Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities. Cash and short term investments are considered very liquid assets.


Highlights and Quick Summary

  • Cash and Short Term Investments for the quarter ending June 29, 2020 was $9.77 Million (a -26.72% decrease compared to previous quarter)
  • Year-over-year quarterly Cash and Short Term Investments increased by 65.35%
  • Annual Cash and Short Term Investments for 2019 was $15.2 Million (a 31.8% increase from previous year)
  • Annual Cash and Short Term Investments for 2018 was $11.5 Million (a -1.92% decrease from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cash and Short Term Investments of Entera Bio Ltd.

Most recent Cash and Short Term Investmentsof ENTX including historical data for past 10 years.

Interactive Chart of Cash and Short Term Investments of Entera Bio Ltd.

Entera Bio Ltd. Cash and Short Term Investments for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $9.77 $13.33
2019 $15.19 $5.91 $7.39 $9.56 $15.19
2018 $11.52 $11.52
2017 $11.75 $11.75

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.